We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Safety and Efficacy of Long-term Somatropin Treatment in Adults (NordiWIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01543880
Recruitment Status : Completed
First Posted : March 5, 2012
Last Update Posted : April 29, 2015
Sponsor:
Information provided by (Responsible Party):

February 28, 2012
March 5, 2012
April 29, 2015
July 2003
December 2013   (Final data collection date for primary outcome measure)
Number of adverse events [ Time Frame: Up to 10 years ]
Same as current
Complete list of historical versions of study NCT01543880 on ClinicalTrials.gov Archive Site
  • BMI (Body Mass Index) [ Time Frame: Up to 10 years ]
  • HbA1c change [ Time Frame: Up to 10 years ]
  • IGF-I (Insulin-Like Growth Factor I) [ Time Frame: Up to 10 years ]
  • Number of patients with carcinoma [ Time Frame: Up to 10 years ]
  • Number of patients with diabetes mellitus [ Time Frame: Up to 10 years ]
  • Co-morbidities associated with growth hormone deficiency [ Time Frame: Up to 10 years ]
Not Provided
Not Provided
 
Safety and Efficacy of Long-term Somatropin Treatment in Adults
Non-interventional Study of Safety and Efficacy of Long-term Somatropin Treatment in Adults
This study is conducted in Europe. The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Adults in need of somatropin or current users
  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency
Drug: somatropin
Prescribed at the discretion of the treating physician according to product labelling
Users of somatropin
Intervention: Drug: somatropin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
752
June 2014
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • In need of somatropin or current user
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01543880
GH-1931
No
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
April 2015